RILA Global Consulting Successfully Completes Rigorous Pharmacovigilance Audit

RILA Global Consulting is proud to announce the successful completion of a comprehensive pharmacovigilance audit with one of the largest pharmaceutical companies in the world. The outcome — no findings and no corrective actions required — demonstrates RILA’s commitment to compliance, data safety, and integrity.

This milestone validates RILA’s leadership in providing pharmacovigilance services, social listening research, and global market insights to some of the most regulated and fast-moving industries in the world. By integrating advanced analytics with compliance excellence, RILA empowers life sciences organizations to meet their regulatory obligations while also gaining actionable business intelligence.

Scope of the Pharmacovigilance Audit

The audit was designed to test the resilience and compliance of RILA’s pharmacovigilance operations across multiple domains. Areas reviewed included:

Safety training compliance — ensuring completion of Adverse Event (AE) reporting responsibilities training, Adverse Medication Reaction (AMR) reporting, Serious Adverse Event (SAE) reporting, Product Quality Complaint (PQC) reporting, Medical Device Complaint (MDC) reporting, Unexpected Therapeutic Effect (UTE) reporting, and At-Risk Scenario (ARS) reporting, along with all other pharmacovigilance safety requirements for vendor personnel.

Quality Management Systems (QMS) — quality controls, assurance processes, and governance frameworks

Data privacy safeguards to protect sensitive healthcare information

Pharmacovigilance data management, including compliant use of IT systems

Data security and retention protocols aligned with international regulations

Standard Operating Procedures (SOPs) — development, approval, training, and enforcement

Contractual documentation such as contracts, agreements, and work orders

Safety information reporting, follow-up procedures, and query resolution

Personnel qualifications and organizational structure, including training records

Business continuity and disaster recovery planning

Information technology infrastructure supporting pharmacovigilance and safety monitoring

Documentation of healthcare professional and patient interactions — including surveys, calls, emails, and other communications

The review included not only documentation but also direct interviews with RILA team members involved in managing project activities.

Why Zero Findings Matter

Pharmaceutical companies face increasing pressure from regulators to maintain robust pharmacovigilance and safety monitoring systems. Passing a global audit with no actions required confirms that RILA’s systems, processes, and work are:

Fully compliant with international pharmacovigilance standards

Built on strong quality and data governance and security practices

Supported by highly trained personnel with validated expertise

Designed to ensure business continuity, patient safety, and regulatory trust

For clients, this means confidence that RILA is more than a vendor — it is a trusted compliance partner.

Beyond Compliance: Social Listening and Market Research Expertise

What sets RILA apart is its ability to integrate compliance with intelligence. Alongside pharmacovigilance operations, RILA provides social listening, digital analytics, and market research services to global pharmaceutical and life sciences companies.

Social listening for pharma helps organizations understand what patients, caregivers, and healthcare professionals are saying across digital platforms. These insights not only identify potential safety signals earlier but also uncover patient sentiment, unmet needs, and treatment experiences.

Market research and shopper insights complement pharmacovigilance by providing a deeper understanding of behavioral drivers, decision-making, and brand perception in healthcare and consumer sectors.

The combination of compliance-driven data management with real-time social insights positions RILA as a leader in future-ready market intelligence.

Setting the Standard for Global Partnerships

By successfully passing this rigorous pharmacovigilance audit, RILA has reinforced its reputation as a trusted partner to some of the world’s largest pharmaceutical organizations.

RILA’s ability to balance regulatory excellence with cutting-edge analytics makes it uniquely positioned to support clients in:

Navigating pharmaceutical compliance and safety reporting requirements

Leveraging social media and real-world data for patient-centric insights

Designing market research strategies that drive innovation and brand growth

Protecting data privacy and information security in highly regulated environments

Looking Forward

RILA Global Consulting remains committed to excellence at the intersection of pharmacovigilance, social listening, and market research. This successful audit outcome is not just a validation of compliance — it is proof of RILA’s role as a global leader in helping pharmaceutical companies stay safe, compliant, and competitive in an evolving healthcare landscape.

RILA Global Consulting Successfully Completes Rigorous Pharmacovigilance Audit